Sun Says FDA Clears Two U.S. Drug Facilities Of GMP Violations
This article was originally published in PharmAsia News
Sun Pharmaceutical said its Caraco Pharmaceutical Laboratories unit in the U.S. has been returned to compliance with good manufacturing practices, having fixed problems that led to U.S. FDA action in 2009.
You may also be interested in...
New York's Avista Capital Partners has taken a 50% stake in Belgian consumer health player Vision Healthcare, which has its sights set on the US market.
Sun Pharma says that the first quarter of financial 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.
The evolution of how and where patients receive their care has received an unexpected boost from the COVID-19 crisis. Coronavirus volume testing challenges persist, but the global medtech industry is now looking beyond the crisis toward a return to “normal” business.